# US Insulin Syringes Market > US Insulin Syringes Market Research Report By Syringe Size (3/10 CC Syringe, 1/2 CC Syringe, 1CC Syringe, Others), By Disease (Type 1 Diabetes, Type 2 Diabetes) and By End-use (Hospitals & Clinics, Homecare Settings, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 3.8% - **2024:** $ 451.78 Million - **2025:** $ 470.89 Million - **2035:** $ 681.1 Million - **Key Players:** Becton Dickinson and Company (US), Novo Nordisk A/S (DK), Sanofi S.A. (FR), Eli Lilly and Company (US), Terumo Corporation (JP), Medtronic plc (IE), Roche Holding AG (CH), Ypsomed AG (CH), Owen Mumford Ltd (GB) **Report ID:** MRFR/Pharma/17408-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-insulin-syringes-market-18954 --- ## Market Summary ## **US Insulin Syringes Market Overview** As per MRFR analysis, the US Insulin Syringes Market Size was estimated at 432.63 (USD Million) in 2023. The US Insulin Syringes Market Industry is expected to grow from 450.8 (USD Million) in 2024 to 799 (USD Million) by 2035. The US Insulin Syringes Market CAGR (growth rate) is expected to be around 5.341% during the forecast period (2025 - 2035). ### **Key US Insulin Syringes Market Trends Highlighted** The US Insulin Syringes Market is currently witnessing significant trends driven by the increasing prevalence of diabetes among the population. With over 37 million Americans living with diabetes according to federal health statistics, the demand for insulin syringes is on the rise. One of the key market drivers is the growing emphasis on diabetes management and patient education, which encourages individuals to effectively manage their condition with proper tools. The push towards more affordable and accessible diabetic care solutions has prompted innovation in the design and manufacturing of insulin syringes, leading to the development of advanced safety features aimed at reducing needle-stick injuries. The market offers several opportunities to be explored, including the integration of digital technology into insulin delivery systems. Smart syringes that can track dosage and timing through mobile applications present a new frontier for patient monitoring and adherence to treatment. Furthermore, as the population ages, there is an expanding market for user-friendly and ergonomic injection devices that cater to seniors, capturing a demographic that may struggle with conventional syringe designs. Recently, the trend of moving towards eco-friendly and sustainable medical products has gained traction in the US. More manufacturers are being prompted to explore biodegradable materials and recyclable packaging to meet consumer demand for environmentally responsible options. The increasing awareness about the environmental impact of disposable medical products has led to more discussions around sustainability in the insulin delivery system sector. Together, these trends reflect a dynamic landscape in the US Insulin Syringes Market, shaped by health needs, technological advancements, and environmental considerations. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **US Insulin Syringes Market Drivers** ### **Increasing Diabetes Prevalence** The prevalence of diabetes in the United States is on the rise, which is a significant driver for the US Insulin Syringes Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 34.2 million Americans, or 10.5% of the population, have diabetes. This upward trend in diabetes cases can lead to a higher demand for insulin syringes, as these devices are essential for diabetes management. Furthermore, the CDC projects that by 2030, the number of adults diagnosed with diabetes will reach approximately 54.9 million. As diabetes management becomes more critical, healthcare organizations like the American Diabetes Association are emphasizing the importance of accessible diabetes management tools, including insulin syringes, fueling market growth. With the increasing focus on patient-centered care and self-management, the US [Insulin Syringes Market](../../../reports/insulin-syringes-market-12070) Industry is positioned for growth as more individuals seek effective solutions for their diabetes management needs. ### **Technological Advancements** Advancements in technology are propelling the US Insulin Syringes Market Industry forward. Innovations in insulin delivery systems, such as the introduction of smart syringes and insulin pens, are enhancing patient convenience and compliance. Research and Development efforts by organizations like Medtronic and Novo Nordisk have led to the creation of devices with features that allow for easier dosage calculations and data tracking. In fact, technological improvements are expected to reduce the risk of medication errors among patients. The US Food and Drug Administration (FDA) has reported a growing interest in regulatory approvals for advanced insulin delivery systems, indicating a positive trend for consumers and manufacturers alike. As these technologies become more integrated into diabetes care routines, the market for insulin syringes will likely expand. ### **Rising Geriatric Population** The aging population in the United States is driving the growth of the US Insulin Syringes Market Industry, as older adults are at a higher risk for developing diabetes. The U.S. Census Bureau projects that the number of Americans age 65 and older will reach 95 million by 2060, an increase from 52 million in 2018. Consequently, the demand for insulin syringes, which are typically used by this demographic for diabetes management, is expected to increase. Organizations such as the Administration for Community Living advocate for accessible healthcare solutions for older adults, which includes providing resources for managing diabetes effectively. This demographic shift indicates that market stakeholders should prepare for growing demand in the coming years, as the geriatric population increasingly relies on insulin syringes to maintain their health. ### **Government Initiatives and Policy Changes** Government initiatives in the United States focused on improving healthcare access are further driving the US Insulin Syringes Market Industry. Recent policy changes, such as the Affordable Care Act and various state-level health programs, have increased coverage for diabetes care, leading to a more significant push for affordable access to insulin and related devices. A report from the Health Resources and Services Administration suggests that over 2.7 million people gained insurance coverage for diabetes management under recent healthcare reforms. As access to insulin syringes becomes more widespread, manufacturers and healthcare providers are poised to see increased usage of their products and services, thus supporting the overall market growth. ## **US Insulin Syringes Market Segment Insights** ### **Insulin Syringes Market Syringe Size Insights** The Syringe Size segment of the US Insulin Syringes Market illustrates a crucial aspect of diabetes management. As the prevalence of diabetes rises in the United States, driven by factors such as obesity, sedentary lifestyles, and an aging population, the demand for insulin syringes tailored to specific dosing needs has become increasingly important. In this context, various syringe sizes including 3/10 CC, 1/2 CC, 1 CC, and others play a significant role in meeting the diverse requirements of patients. The 3/10 CC syringe, often favored for its precision in delivering small doses, is popular among patients requiring very accurate insulin delivery. Conversely, the 1/2 CC syringe caters to individuals needing slightly higher doses, proving valuable for those on more intensive insulin regimens. The 1 CC syringe serves as a versatile option for users requiring larger doses or for those administering other medications. Furthermore, the category labeled 'Others' encompasses a range of variations that cater to specialty needs or preferences of certain demographics, thus widening the accessibility to necessary treatment for diabetes management. This segment underscores a growing trend where patients select syringe sizes based not only on their dosage requirements but also on comfort and ease of use. US Insulin Syringes Market Statistics reveal that advancements in technology are enhancing the design and functionality of syringes, leading to improved user experience and adherence to treatment protocols. Market growth is also being driven by educational initiatives and support programs for patients, promoting awareness of the importance of accurate dosing, which directly influences the choice of syringe size. As the market evolves, there are significant opportunities for manufacturers to innovate within the Syringe Size segment, including enhancements in safety features and ease of use. Understanding these insights into the market segmentation is vital for stakeholders aiming to effectively address the needs of diabetic patients and cater to a growing demand for insulin delivery systems in the United States. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ### **Insulin Syringes Market Disease Insights** The US Insulin Syringes Market, particularly within the Disease segment, encompasses critical healthcare needs revolving around diabetes management. Type 1 Diabetes and Type 2 Diabetes are the primary conditions driving demand for insulin delivery solutions, such as syringes. In the US, the prevalence of diabetes has steadily increased, necessitating innovative products for effective disease management. Type 1 Diabetes, often diagnosed in children and young adults, requires consistent insulin administration, making the reliability and efficiency of syringes paramount. Conversely, Type 2 Diabetes, which predominantly affects adults, accounts for the majority of diabetes cases and has become a leading health concern, linked to lifestyle factors and obesity. As the healthcare industry continues to prioritize diabetes care, advancements in syringe technology, such as design improvements for comfort and accuracy, offer significant opportunities within this market. Furthermore, the growing health awareness among the population and increased accessibility to healthcare services will likely enhance the utility of insulin syringes, catering to a broad spectrum of patient needs across both diabetes types. The emphasis on patient-centered care and effective self-management reflects the evolving landscape of diabetes treatment in the US, making this segment essential in addressing public health challenges. ### **Insulin Syringes Market End-use Insights** The US Insulin Syringes Market, categorized by End-use, presents a comprehensive landscape dominated by several application segments including Hospitals and Clinics, Homecare Settings, and Others. Hospitals and Clinics are critical players in the market, providing necessary environments for immediate medical care and diabetes management; they cater primarily to patients requiring chronic disease management, thereby driving demand for insulin syringes. Homecare Settings have seen substantial growth, especially with the rising trend of self-monitoring of blood glucose among diabetes patients, allowing individuals to manage their health from the comfort of their homes. This shift is often supported by technological advancements ensuring the availability of user-friendly insulin delivery solutions. Additionally, the Others segment, which includes specialized care programs and travel-related insulin administration, also contributes to the overall dynamics of the market. The burgeoning population struggling with diabetes in the US, which has exceeded 37 million according to health statistics, indicates an increasing reliance on insulin syringes across these segments. As such, the US Insulin Syringes Market segmentation shows robust growth opportunities driven by the rise in diabetes prevalence and an increasing preference for insulin therapy across various settings. ## **US Insulin Syringes Market Key Players and Competitive Insights** The US Insulin Syringes Market has experienced significant growth and transformation in recent years, driven by the increasing prevalence of diabetes and the consequently rising demand for insulin delivery systems. The competitive landscape is characterized by well-established players and a number of emerging companies that focus on innovation and technological advancements in syringe design and functionality. As the market evolves, factors such as regulatory changes, pricing pressures, and the push for better patient outcomes have led firms to adapt their strategies to maintain market share and competitive advantage. Companies are increasingly investing in research and development to improve the efficacy and user-friendliness of their products, ensuring they meet the evolving needs of healthcare providers and patients alike. The landscape is also influenced by significant partnerships, mergers, and acquisitions that are aimed at expanding product offerings and enhancing distribution channels. ### **Merck and Co** Merck and Co stands out in the competitive environment of the US Insulin Syringes Market through its strong presence and commitment to improving diabetes care. The company benefits from a robust reputation for quality and innovation, which bolsters consumer trust in its insulin delivery solutions. Merck and Co has strategically focused on enhancing the effectiveness of its syringe technology, thereby catering to both healthcare providers and patients. The firm’s extensive network in the healthcare sector allows it to establish strong partnerships with physicians and clinics, enhancing its market penetration. Additionally, its active involvement in market research and development ensures that it stays ahead of industry trends, allowing the company to promptly respond to patient needs and regulatory requirements. Merck and Co’s strong financial position enables it to continually invest in new product development, further solidifying its competitive stance in the market. ### **AstraZeneca** AstraZeneca has made notable strides in the US Insulin Syringes Market, focusing on delivering innovative solutions for diabetes management. The company’s portfolio includes a range of products designed for insulin delivery, which are widely used within the healthcare community due to their reliability and user-friendly features. AstraZeneca's emphasis on research and development has positioned it at the forefront of advancements in insulin delivery technology. The firm actively engages in strategic collaborations and partnerships, which enhance its product offerings and distribution capabilities. Key products from AstraZeneca not only include insulin delivery devices but also encompass patient education resources that support effective diabetes management. The company’s strength lies in its commitment to improving patient outcomes, as well as its ability to adapt to changes in the regulatory landscape, thereby ensuring compliance and safety. Through calculated mergers and acquisitions, AstraZeneca has broadened its operational reach in the US market, enabling it to leverage synergies and bolster its competitive edge. ### **Key Companies in the US Insulin Syringes Market Include** ## **US Insulin Syringes Market Industry Developments** In recent months, the US Insulin Syringes Market has seen noteworthy developments, particularly surrounding major players such as Merck and Company, AstraZeneca, and Eli Lilly and Company. There has been an increasing focus on the affordability and accessibility of insulin, leading to discussions about regulatory reforms aimed at lowering prices. In August 2023, Medtronic announced advancements in their insulin delivery systems that enhance patient experience and ease of use. Furthermore, the market is experiencing a significant growth trajectory, with a valuation boost driven by demand for innovative and user-friendly diabetes management solutions. In the merger and acquisition landscape, Becton Dickinson and Company announced the acquisition of a smaller biotech firm specializing in advanced injection devices in July 2023, positioning them to expand their product offerings in the insulin delivery space. Additionally, Novo Nordisk has reported substantial economic growth in their insulin syringe division following strategic investments in Research and Development. Overall, the US insulin syringes landscape continues to evolve with a strong emphasis on improving patient accessibility and innovative solutions to address chronic diabetes needs. ## **US Insulin Syringes Market Segmentation Insights** ### **Insulin Syringes Market Syringe Size Outlook** ### **Insulin Syringes Market Disease Outlook** ### **Insulin Syringes Market End-use Outlook** ## Market Drivers ### Rising Diabetes Prevalence The increasing prevalence of diabetes in the United States is a primary driver of the US insulin syringes market. According to the Centers for Disease Control and Prevention (CDC), approximately 34.2 million Americans, or 10.5% of the population, have diabetes. This growing demographic necessitates a higher demand for [insulin delivery devices](https://www.marketresearchfuture.com/reports/insulin-delivery-devices-market-851), including syringes. As more individuals are diagnosed with diabetes, the need for effective management solutions becomes paramount. The US insulin syringes market is likely to experience sustained growth as healthcare providers emphasize the importance of insulin therapy in managing diabetes. Furthermore, the aging population, which is more susceptible to diabetes, contributes to this trend, indicating a potential increase in market size and opportunities for manufacturers. ### Increased Focus on Preventive Healthcare The growing emphasis on preventive healthcare in the United States is driving the US insulin syringes market. Healthcare providers are increasingly advocating for early diagnosis and management of diabetes to prevent complications. This shift towards preventive care has led to a rise in screening programs and educational initiatives aimed at raising awareness about diabetes management. As patients become more informed about their health, the demand for insulin syringes is expected to increase. The US insulin syringes market is likely to benefit from this trend, as healthcare systems prioritize effective management solutions for chronic conditions. This focus on prevention may also encourage innovation in syringe design and delivery methods, further enhancing market growth. ### Rising Demand for Home Healthcare Solutions The trend towards [home healthcare](https://www.marketresearchfuture.com/reports/home-healthcare-market-2030) solutions is significantly impacting the US insulin syringes market. With more patients opting for self-management of their diabetes, the demand for insulin syringes is on the rise. Home healthcare allows individuals to administer their insulin conveniently, leading to better adherence to treatment regimens. According to a report by the American Diabetes Association, self-management practices are associated with improved health outcomes. This shift towards home-based care is likely to drive the US insulin syringes market, as manufacturers respond to the growing need for user-friendly and accessible insulin delivery devices. As the population ages and more individuals seek to manage their diabetes at home, the market is expected to expand. ### Technological Innovations in Syringe Design Technological advancements in syringe design are significantly influencing the US insulin syringes market. Innovations such as safety-engineered syringes, which reduce the risk of needlestick injuries, are becoming increasingly prevalent. The introduction of prefilled syringes and insulin pens has also transformed the way patients administer insulin, enhancing convenience and compliance. According to the FDA, the approval of new syringe technologies has surged, reflecting the industry's commitment to improving patient outcomes. These advancements not only cater to the needs of patients but also align with regulatory standards aimed at ensuring safety and efficacy. As a result, the US insulin syringes market is poised for growth, driven by the demand for more user-friendly and safer insulin delivery options. ### Government Initiatives and Healthcare Policies Government initiatives and healthcare policies play a crucial role in shaping the US insulin syringes market. Programs aimed at increasing access to diabetes care, such as the Affordable Care Act, have expanded insurance coverage for insulin and related devices. This has led to a rise in the number of patients seeking insulin therapy, thereby boosting the demand for syringes. Additionally, state-level initiatives promoting diabetes education and management further support the market. The US insulin syringes market benefits from these policies, as they encourage manufacturers to innovate and provide affordable solutions. As healthcare policies continue to evolve, they are likely to create new opportunities for growth within the market. ## Future Outlook The US insulin syringes market is projected to grow at a 3.8% CAGR from 2025 to 2035, driven by increasing diabetes prevalence and technological advancements. **New opportunities:** - Expansion of telehealth services for remote patient monitoring Development of eco-friendly, biodegradable syringe materials Partnerships with pharmacies for automated insulin dispensing solutions By 2035, the market is expected to be robust, driven by innovation and strategic partnerships. ## Segment Insights ### By Application: Diabetes Management (Largest) vs. Insulin Delivery (Fastest-Growing) In the US insulin syringes market, the application segment is primarily dominated by Diabetes Management, which accounts for the largest portion of the market share. This segment is driven by a significant population affected by diabetes, necessitating effective management solutions. Following closely is the Insulin Delivery segment, which is gaining ground as innovations in delivery methods enhance convenience and efficiency for patients. Research and Development and Clinical Trials also contribute to the overall dynamics but represent smaller shares of the market. Diabetes Management (Dominant) vs. Insulin Delivery (Emerging) Diabetes Management remains a dominant force in the US insulin syringes market, reflecting the urgent need for consistent and effective diabetes care. This segment encompasses a comprehensive approach, including patient education, regular monitoring, and timely administration of insulin. On the other hand, Insulin Delivery is an emerging segment, characterized by the introduction of advanced delivery systems that offer improved flexibility and user adherence. The rising demand for user-friendly delivery options highlights its potential for rapid growth, especially as manufacturers innovate to meet the changing needs of diabetic patients. ### By End Use: Hospitals (Largest) vs. Diabetes Clinics (Fastest-Growing) In the US insulin syringes market, the end-use segments are characterized by distinct market shares. Hospitals continue to dominate the market due to their significant demand for insulin syringes as a staple in diabetes management among inpatients. Following hospitals, pharmacies play an important role as well, supplying quality syringes to outpatient diabetes patients, reflecting a robust utilization in personal healthcare. Diabetes clinics, though smaller in market share, are rapidly gaining ground due to their specialized services targeting diabetic patients, enhancing awareness and education surrounding insulin administration. Hospitals (Dominant) vs. Diabetes Clinics (Emerging) Hospitals remain the dominant segment in the end-use category for insulin syringes, primarily because they cater to a higher volume of patients requiring immediate diabetes management. These healthcare institutions are fully equipped with necessary resources for various diabetic care services. In contrast, diabetes clinics are emerging as a significant player, focusing on personalized diabetes management and education. Their growing popularity stems from the increasing prevalence of diabetes and the need for specialized care, positioning them well for future growth in the market. As patient preference shifts towards more tailored healthcare solutions, diabetes clinics are likely to expand their market share in the coming years. ### By Syringe Type: Insulin Pens (Largest) vs. Safety Syringes (Fastest-Growing) In the US insulin syringes market, the market share distribution among various syringe types indicates a clear preference for insulin pens, which dominate the segment due to their convenience and ease of use. Following insulin pens are standard syringes, which maintain a significant portion of the market share. [Safety syringes](https://www.marketresearchfuture.com/reports/safety-syringe-market-32499), while currently smaller in share, are gaining traction rapidly, as healthcare providers prioritize the need for safety and needle-stick injury prevention in their practices. Safety Syringes (Dominant) vs. Prefilled Syringes (Emerging) Safety syringes have become dominant in the market as they combine the traditional functionalities of standard syringes with innovative safety features designed to minimize the risk of needle-stick injuries. The heightened awareness around health hazards and clear regulatory shifts towards safer needle technologies contribute to their prominent position. In contrast, prefilled syringes are emerging strongly due to their user-friendly design and reduced preparation time, particularly appealing to both patients and providers. The convenience of these prefilled options creates a seamless experience for insulin administration, positioning them as a notable trend within the segment. ### By Needle Gauge: Ultra-Fine Gauge (Largest) vs. Low Gauge (Fastest-Growing) In the US insulin syringes market, the needle gauge plays a critical role in user convenience and effectiveness. Among the various categories, Ultra-Fine Gauge syringes command the largest share, preferred by users for their minimal discomfort and optimal insulin delivery. Meanwhile, Low Gauge syringes represent the fastest-growing segment as they gain traction among new users opting for larger bore sizes for a more efficient insulin administration experience. This shift in preference highlights changing user attitudes towards needle gauge selection. Growth trends in this segment are largely influenced by increasing diabetes prevalence and the rising education on effective insulin administration. The demand for Ultra-Fine Gauge syringes continues to rise as users prioritize comfort, while Low Gauge syringes are becoming an attractive option for those who seek a balance between speed and ease of use. Innovations in manufacturing processes have further enabled the creation of finer and more specialized syringes, catering to diverse user needs. Ultra-Fine Gauge (Dominant) vs. Low Gauge (Emerging) Ultra-Fine Gauge syringes dominate the market due to their ability to deliver precise doses of insulin with minimal pain, making them the preferred choice for daily users. Their design emphasizes user comfort and improved therapeutic outcomes, which resonate well with patients managing diabetes. On the other hand, Low Gauge syringes are emerging as a popular alternative, appealing particularly to a demographic seeking quicker administration of larger insulin volumes. This segment is characterized by a growing focus on simplifying the injection process. While Ultra-Fine Gauge syringes maintain a solid position for their efficiency, the increasing acceptance of Low Gauge options highlights a significant trend toward personalization in insulin delivery systems. ## Competitive Benchmarking The competitive dynamics of the insulin syringes market in the US reflect a landscape characterized by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Becton Dickinson and Company (US), Eli Lilly and Company (US), and Novo Nordisk A/S (DK) are at the forefront, each employing distinct strategies to enhance their market positioning. Becton Dickinson, for instance, emphasizes innovation in product design and technology integration, aiming to improve user experience and safety. Eli Lilly, on the other hand, focuses on expanding its product portfolio through strategic acquisitions and partnerships, thereby enhancing its competitive edge. Novo Nordisk appears to prioritize sustainability and digital health solutions, which collectively shape a competitive environment that is increasingly focused on meeting the evolving needs of patients and healthcare providers. The market structure is moderately fragmented, with several players vying for market share through various business tactics. Localizing manufacturing and optimizing supply chains are prevalent strategies among these companies, allowing them to respond swiftly to market demands and regulatory changes. The collective influence of these key players fosters a competitive atmosphere where innovation and operational efficiency are paramount, driving the market forward. In December 2025, Becton Dickinson and Company (US) announced the launch of a new smart insulin syringe designed to enhance dosing accuracy and patient adherence. This strategic move underscores the company's commitment to leveraging technology to improve patient outcomes, potentially setting a new standard in the market. The introduction of such innovative products may not only bolster Becton Dickinson's market share but also influence competitors to accelerate their own product development initiatives. In November 2025, Eli Lilly and Company (US) entered into a partnership with a leading digital health firm to integrate advanced data analytics into its insulin delivery systems. This collaboration aims to provide patients with personalized insights and support, thereby enhancing treatment adherence. The strategic importance of this partnership lies in its potential to position Eli Lilly as a leader in the digital transformation of diabetes care, aligning with current trends towards personalized medicine. In October 2025, Novo Nordisk A/S (DK) announced a significant investment in sustainable manufacturing practices, aiming to reduce its carbon footprint by 30% by 2030. This initiative not only reflects the company's commitment to environmental responsibility but also aligns with the growing consumer demand for sustainable healthcare solutions. Such strategic actions may enhance Novo Nordisk's brand reputation and appeal to environmentally conscious consumers, further differentiating it in a competitive market. As of January 2026, the insulin syringes market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence (AI) in product development. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise to drive innovation. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and deliver high-quality, patient-centric solutions. ## Recent News & Developments In recent months, the US Insulin Syringes Market has seen noteworthy developments, particularly surrounding major players such as Merck and Company, AstraZeneca, and Eli Lilly and Company. There has been an increasing focus on the affordability and accessibility of insulin, leading to discussions about regulatory reforms aimed at lowering prices. In August 2023, Medtronic announced advancements in their insulin delivery systems that enhance patient experience and ease of use. Furthermore, the market is experiencing a significant growth trajectory, with a valuation boost driven by demand for innovative and user-friendly diabetes management solutions. In the merger and acquisition landscape, Becton Dickinson and Company announced the acquisition of a smaller biotech firm specializing in advanced injection devices in July 2023, positioning them to expand their product offerings in the insulin delivery space. Additionally, Novo Nordisk has reported substantial economic growth in their insulin syringe division following strategic investments in Research and Development. Overall, the US insulin syringes landscape continues to evolve with a strong emphasis on improving patient accessibility and innovative solutions to address chronic diabetes needs. ## Report Scope | MARKET SIZE 2024 | 451.78(USD Million) | | --- | --- | | MARKET SIZE 2025 | 470.89(USD Million) | | MARKET SIZE 2035 | 681.1(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.8% (2024 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Becton Dickinson and Company (US), Novo Nordisk A/S (DK), Sanofi S.A. (FR), Eli Lilly and Company (US), Terumo Corporation (JP), Medtronic plc (IE), Roche Holding AG (CH), Ypsomed AG (CH), Owen Mumford Ltd (GB) | | Segments Covered | Application, End Use, Syringe Type, Needle Gauge | | Key Market Opportunities | Integration of smart technology in insulin syringes enhances patient adherence and monitoring capabilities. | | Key Market Dynamics | Rising demand for insulin syringes driven by increasing diabetes prevalence and evolving patient care practices in the US. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US insulin syringes market?** A: The US insulin syringes market was valued at approximately 451.78 USD Million in 2024. **Q: What is the projected market valuation for the US insulin syringes market by 2035?** A: The market is expected to reach a valuation of around 681.1 USD Million by 2035. **Q: What is the expected CAGR for the US insulin syringes market during the forecast period?** A: The expected CAGR for the US insulin syringes market from 2025 to 2035 is 3.8%. **Q: Which companies are considered key players in the US insulin syringes market?** A: Key players include Becton Dickinson and Company, Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company, and others. **Q: What are the main applications of insulin syringes in the market?** A: The main applications include Diabetes Management, Insulin Delivery, Research and Development, and Clinical Trials. **Q: How does the market segment by end use for insulin syringes?** A: The market segments by end use include Hospitals, Home Care, Diabetes Clinics, and Pharmacies. **Q: What types of syringes are available in the US insulin syringes market?** A: Available types include Standard Syringes, Safety Syringes, Insulin Pens, and Prefilled Syringes. **Q: What needle gauges are utilized in the US insulin syringes market?** A: The market features needle gauges such as Low Gauge, Medium Gauge, High Gauge, and Ultra-Fine Gauge. **Q: What was the valuation of the Diabetes Management segment in 2024?** A: The Diabetes Management segment was valued at approximately 180.0 USD Million in 2024. **Q: What is the projected growth for the Insulin Delivery segment by 2035?** A: The Insulin Delivery segment is projected to grow to around 220.0 USD Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-insulin-syringes-market-18954*